Novel triple-drug cocktail for glioblastoma exhibits potent synergistic antitumoral effects

Introduction: Glioblastoma (GBM) is the most common and lethal primary brain cancer and remains incurable mainly due to limited drug action at the tumor site, systemic toxicity, and resistance mechanisms including chemoresistance and immunosuppression. Indeed, GBM tumors often display high levels of DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) to correct the damage induced by the standard-of-care drug temozolomide (TMZ), leading to tumor cell survival and poor prognosis (1). Moreover, GBM’s immunosuppressive and “cold” nature renders most immunotherapies ineffective (2).